The study, which has not been peer-reviewed, was conducted from Feb. 4 to Feb. 28 and involved 62 COVID-19 patients admitted to a hospital in Wuhan, China. About 31 patients received hydroxychloroquine in addition to the usual care provided to COVID-19 patients, while the rest only received the usual treatments, which included oxygen, antiviral drugs and antibiotics, The New York Times reports.
Researchers found patients in the hydroxychloroquine group experienced reductions in fevers and coughs a day or so earlier than those in the usual care group, the Times reports.
Also, about 80 percent of the patients in the hydroxychloroquine group experienced improvement in pneumonia compared to 54 percent of the usual care group.
Four patients progressed to severe illnesses, and they were all from the usual care group.
But two patients did experience mild adverse reactions in the hydroxychloroquine group.
There has been a lot of excitement around the potential benefits of adding hydroxychloroquine to the treatment regimen of coronavirus patients, after previous reports of its potential efficacy from China and France, though those reports did not include control groups, as well as comments by President Donald Trump, according to the Times. But this has led to hoarding and shortages of the malaria drug.
More articles on infection control:
Is 6 feet apart enough? COVID-19 droplets may travel up to 27 feet, MIT researcher says
Novel coronavirus contaminates patient environment, new evidence shows
Some COVID-19 patients only show digestive symptoms, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.